

SRT-3025 hydrochloride


ALTERNATE NAME:

5-(3-methoxypropyl)-2-phenyl-N-(2-(6-(pyrrolidin-1-ylmethyl)thiazolo[5,4-b]pyridin-2-yl)phenyl)thiazole-4carboxamide hydrochloride SRT3025 HCl

CATALOG #:

B2376-5 5 mg B2376-25 25 mg

STRUCTURE:



MOLECULAR FORMULA:	$C_{3\ 1}\ H_{3\ 2}\ CIN_5\ O_2\ S_2$
MOLECULAR WEIGHT:	606.2
CAS NUMBER:	2070015-26-6
APPEARANCE:	Crystalline solid
PURITY:	≥98% by HPLC
SOLUBILITY:	>50 mg/ml DMSO
DESCRIPTION:	SRT-3025 is a potent and selective Sirt1 activator. It inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival. SRT-3025 inhibits RANKL-induced osteoclastogenesis in bone marrow-derived macrophages (BMMs) by activating AMPK and deacetylating ReIA/p65 lysine 310, critical for activation of the NF-kB signaling pathway.
REFERENCES:	
HANDLING:	Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
RELATED PRODUCTS:	
SirtACt (2741) Piceatannol (2072) Resveratrol (1758) SIRT1720 (2772) BML-278 (2379)	
DISCLAIMER:	FOR RESEARCH USE ONLY! Not to be used on humans.